BIOMARKER:

PALB2 mutation

News alerts, weekly reports and conference planners

Entrez ID:

79728

Related biomarkers:

CNA

Others

‹

›

PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
PALB2 mutation	Prostate Cancer	PALB2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2
PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2
PALB2 mutation	Ovarian Cancer	PALB2 mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
PALB2 mutation	Breast Cancer	PALB2 mutation	Breast Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
PALB2 mutation	Ovarian Cancer	PALB2 mutation	Ovarian Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
PALB2 mutation	Pancreatic Cancer	PALB2 mutation	Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2
PALB2 mutation	Pancreatic Cancer	PALB2 mutation	Pancreatic Cancer	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
PALB2 mutation	Breast Cancer	PALB2 mutation	Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
PALB2 mutation	Urothelial Cancer	PALB2 mutation	Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
PALB2 mutation	Triple Negative Breast Cancer	PALB2 mutation	Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
PALB2 mutation	Hormone Receptor Positive Breast Cancer	PALB2 mutation	Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials lenvatinib Resistant : C3	lenvatinib Resistant: C3 – Early Trials lenvatinib Resistant : C3
PALB2 mutation	Pancreatic Cancer	PALB2 mutation	Pancreatic Cancer	oxaliplatin Sensitive: C3 – Early Trials oxaliplatin Sensitive : C3	oxaliplatin Sensitive: C3 – Early Trials oxaliplatin Sensitive : C3
PALB2 mutation	Prostate Cancer	PALB2 mutation	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	ipilimumab + niraparib Sensitive: C3 – Early Trials ipilimumab + niraparib Sensitive : C3	ipilimumab + niraparib Sensitive: C3 – Early Trials ipilimumab + niraparib Sensitive : C3
PALB2 mutation	Endometrial Cancer	PALB2 mutation	Endometrial Cancer	rucaparib + E 3810 Sensitive: C4 – Case Studies rucaparib + E 3810 Sensitive : C4	rucaparib + E 3810 Sensitive: C4 – Case Studies rucaparib + E 3810 Sensitive : C4
PALB2 mutation	Triple Negative Breast Cancer	PALB2 mutation	Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: D – Preclinical carboplatin + docetaxel Sensitive : D	carboplatin + docetaxel Sensitive: D – Preclinical carboplatin + docetaxel Sensitive : D

PALB2 mutation

Associations